• Citer

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

par Wells, Athol U;Flaherty, Kevin R;Brown, Keith;Inoue, Yoshikazu;Devaraj, Anand;Richeldi, Luca;Moua, Teng;Crestani, Bruno;Wuyts, Wim;Stowasser, Susanne;Quaresma, Manuel;Goeldner, Rainer Georg;Schlenker-Herceg, Rozsa;Bondue, Benjamin ;INBUILD trial investigators, Martin;Kolb,
Référence The Lancet. Respiratory medicine, 8, 5, page (453-460)
Publication Publié, 2020-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis.